From Wikipedia, the free encyclopedia
Douglas R. Lowy
Douglas R. Lowy, MD, Principal Deputy Director, National Cancer Institute
Alma mater
Awards Lasker-DeBakey Clinical Medical Research Award (2017) Sabin Gold Medal (2011)
Scientific career
Fields Cancer biology

Douglas R. Lowy (born c. 1940s) is the current Principal Deputy Director of the U.S. National Cancer Institute (NCI) and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy served as Acting Director of NCI between April 2015 and October 2017 following the resignation of Harold E. Varmus, M.D., [1] [2] and again between April and November 2019, while Director Norman Sharpless served as the Acting Commissioner of the U.S. Food and Drug Administration. [3] He resumed the role of Acting Director on May 1, 2022, when Sharpless stepped down until October 3, 2022 when Monica Bertagnolli was appointed Director. [4] [5] He resumed the role again in November 2023 after Bertagnolli resigned to serve as director of the National Institutes of Health. [6]

Lowy has served as Deputy Director of the NCI since 2010, alongside former directors Varmus and Sharpless and current director Bertagnolli. [7] Lowy was co-recipient (along with Dr. John T. Schiller) of the National Medal of Technology and Innovation in 2014 [8] and the Lasker-DeBakey Clinical Medical Research Award in 2017. [9]

Biography

Lowy received his medical degree from the New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale. He has directed a research laboratory at NCI since 1975, after receiving training as a Research Associate in the National Institute of Allergy and Infectious Diseases. Lowy is a member of the National Academy of Sciences (NAS) and of its Institute of Medicine. For his joint research with John T. Schiller on technology that enabled the development of preventive human papillomavirus (HPV) vaccines, he and Schiller received the 2007 Samuel J. Heyman Service to America Medal, [10] the 2011 Albert B. Sabin Gold Medal, [11] the 2012 National Medal of Technology and Innovation (awarded in 2014), and the Lasker-DeBakey Clinical Medical Research Award in 2017. [9] He has also received the National Medal of Honor for Basic Research from the American Cancer Society. [12]

Research activities

Lowy's HPV research, conducted in collaboration with John T. Schiller, has characterized the HPV oncoproteins E6 and E7. [13] [14]

Awards

References

  1. ^ "Douglas Lowy named Acting Director of the National Cancer Institute". Website of the National Cancer Institute. April 2015. Retrieved 1 April 2015. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ Tavernise, Sabrina (March 4, 2015). "Chief of National Cancer Institute Resigns". The New York Times. Retrieved 16 July 2015.
  3. ^ Kaplan, Sheila (2019-03-12). "National Cancer Chief, Ned Sharpless, Named F.D.A.'s Acting Commissioner". The New York Times. ISSN  0362-4331. Retrieved 2019-03-17.
  4. ^ "Monica Bertagnolli becomes NCI director - NCI". 3 October 2022.
  5. ^ "NCI Acting Director Dr. Douglas R. Lowy - National Cancer Institute". www.cancer.gov. 2019-11-01. Retrieved 2022-05-02.
  6. ^ "Monica Bertagnolli, M.D., takes the helm at NIH". 9 November 2023.
  7. ^ "NCI Principal Deputy Director Dr. Douglas R. Lowy - National Cancer Institute". www.cancer.gov. 2019-11-01. Retrieved 2022-03-24.
  8. ^ "President Obama Presents the National Medals of Science & National Medals of Technology and Innovation". whitehouse.gov. 20 November 2014. Retrieved 2 April 2015 – via National Archives.
  9. ^ a b c Foundation, Lasker. "HPV vaccines for cancer prevention | The Lasker Foundation". The Lasker Foundation. Retrieved 2018-06-19.
  10. ^ "2007 Federal Employees of the Year". Service to America Medals. Archived from the original on January 8, 2015. Retrieved 2015-04-02.
  11. ^ "Sabin Gold Medal Award". Retrieved 2 April 2015.
  12. ^ "American Cancer Society to Present Highest Honor for Outstanding Contributions to Cancer Fight". American Cancer Society. Archived from the original on 14 September 2015. Retrieved 2 April 2015.
  13. ^ Androphy, EJ; Hubbert, NL; Schiller, JT; Lowy, DR (April 1987). "Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines". The EMBO Journal. 6 (4): 989–92. doi: 10.1002/j.1460-2075.1987.tb04849.x. PMC  553493. PMID  3036495.
  14. ^ Hawley-Nelson, P; Vousden, KH; Hubbert, NL; Lowy, DR; Schiller, JT (1 December 1989). "HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes". The EMBO Journal. 8 (12): 3905–10. doi: 10.1002/j.1460-2075.1989.tb08570.x. PMC  402081. PMID  2555178.
  15. ^ a b c d e f "Douglas R. Lowy, MD". American Association for Cancer research. Retrieved 16 July 2015.
  16. ^ Barr, Stephen (September 10, 2007). "Work on Cervical Cancer Vaccine Puts NIH Duo in the Running for Major Award". The Washington Post. Retrieved 16 July 2015.
  17. ^ "Laureates". Novartis Prizes for Immunology. 3 October 2011. Archived from the original on 29 August 2018. Retrieved 29 August 2018.
  18. ^ "Douglas R. Lowy, MD, Receives Harrington Prize for Innovation in Medicine". ASCO Post. March 10, 2015. Retrieved 16 July 2015.
  19. ^ Lowy, Douglas R. (4 January 2016). "HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions". Journal of Clinical Investigation. 126 (1): 5–11. doi: 10.1172/JCI85446. PMC  4701560. PMID  26727228.
  20. ^ "Szent-Györgyi Prize to honor NCI's Douglas R. Lowy and John T. Schiller". National Cancer Institute. 15 February 2018. Retrieved 4 October 2019.

External links

Retrieved from " https://en.wikipedia.org/?title=Douglas_R._Lowy&oldid=1193441933"